Abstract

Addressing limitations in standard obesity treatments, this paper proposes the CM4 (Cardiometabolic Quadruple) protocol—a non-invasive, chronotherapeutic approach using empagliflozin, thiazide diuretics, L-arginine, and potassium citrate. This strategy aims to manage visceral fat and cardiometabolic risks through induced glucosuria, focusing on metabolic improvement while sparing lean tissue [1, 2, 3].

Introduction

Conventional obesity treatments, such as GLP-1 receptor agonists and bariatric surgery, often cause significant gastrointestinal distress, loss of lean muscle mass, and high recidivism rates. The CM4 protocol is designed as a multi-target, non-invasive alternative that avoids central nervous system and gastrointestinal disruption [1, 2]. By focusing on renal and vascular mechanisms rather than appetite suppression, it aims to reduce metabolic syndrome without sacrificing structural tissue.

Molecular Mechanisms and Chronotherapeutic Synchronization

CM4 efficacy relies on time-dependent, three-phase daily dosing to manage renal transport and systemic electrolyte balances:

• Morning Phase (Empagliflozin + Thiazide): Induces glucosuria and natriuresis, lowering insulin and raising glucagon to shift metabolism toward fat oxidation [1, 3].

  
  

• Midday Phase (L-Arginine): Provides endothelial nitric oxide, aimed at reducing vascular resistance.

  
  

• Evening Phase (Potassium Citrate): Replaces electrolytes and provides buffering agents to manage potential acidosis [4].

  
  

Comparative Analysis: Tissue Selectivity and Reversibility

Unlike conventional interventions, the CM4 protocol aims to be anatomically conservative, potentially sparing lean mass  while offering reversible control over cardiometabolic markers.

Clinical Surveillance and Patient Selection

Given the impact on renal and electrolyte balance, the protocol requires careful surveillance. Eligible patients with visceral obesity must maintain adequate renal function (eGFR >45 mL/min/1.73m²), with close monitoring of electrolytes, creatinine, and ketone levels to prevent complications.

Conclusion

The CM4 protocol offers a potential, targeted, and non-invasive approach to managing visceral obesity, aiming to overcome the limitations of current pharmaceutical and surgical strategies.